5 Results for "

IgG autoantibodies

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "IgG autoantibodies" in MCE Product Catalog:

1
L-α-Phosphatidylinositol
L-α-Phosphatidylinositol
0 Images
1 Cited Publications
Cat. No.: HY-W020658
CAS No.: 97281-52-2
Category:  

Natural Products Leguminosae Glycine max (L.) merr Plants

Target:  

HIV

L-α-Phosphatidylinositol is a type of phospholipid. L-α-Phosphatidylinositol can serve as an antigen in ELISA assays for screening antiphospholipid antibodies. L-α-Phosphatidylinositol can be used in studies related to HIV-1 infection .
loading...
    loading...
View All Sizes
Efgartigimod alfa
Efgartigimod alfa
0 Images
Cat. No.: HY-147305
CAS No.: 1821402-21-4
Synonyms: ARGX-113

Target:  

Fc Receptor (FcR)

Research Areas:  

Cardiovascular Disease Inflammation/Immunology

Efgartigimod alfa (ARGX-113) is a reversibility, humanized Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research .
loading...
    loading...
View All Sizes
ART5803
ART5803
0 Images
Cat. No.: HY-P991611
CAS No.: 3058434-76-4

Target:  

iGluR

Research Areas:  

Inflammation/Immunology

ART5803 is a humanized IgG1 monoclonal antibody inhibitor targeting NMDAR. ART5803 binds to the N-terminal domain (NTD) of the NMDAR GluN1 subunit (GluN1-NTD) with a high affinity. ART5803 blocks NMDAR internalization induced by pathogenic autoantibodies and restores cell-surface NMDAR expression and functions. ART5803 reverses behavioral abnormalities and NMDAR expression in marmoset disease models. ABT-147 can be used to study anti-NMDAR encephalitis .
loading...
    loading...
View All Sizes
Ripertamab
Ripertamab
0 Images
Cat. No.: HY-P99952
CAS No.: 2249927-04-4
Synonyms: SCT400

Target:  

CD20

Research Areas:  

Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer

Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonal antibody. As an immunomodulator, ripertamab reduces the levels of pathogenic autoantibodies, alleviates immune complex deposition, and blocks the antigen-presenting function of cells. Ripertamab depletes CD20-positive cells. Ripertamab can induce infusion-related reactions, pulmonary toxicity, neutropenia and thrombocytopenia. Ripertamab is applicable to research related to non-Hodgkin's lymphoma, primary membranous nephropathy and idiopathic membranous nephropathy .
loading...
    loading...
View All Sizes
1Z105
1Z105
0 Images
Cat. No.: HY-117573
CAS No.: 1438280-73-9
Target:  

Toll-like Receptor (TLR) NF-κB Interleukin Related Influenza Virus

Research Areas:  

Infection Metabolic Disease Inflammation/Immunology

1Z105 is an orally active TLR4/MD2 agonist, immunostimulant and vaccine adjuvant. 1Z105 activates NF-κB via the MyD88/TRIF pathway in a CD14-independent manner, with EC50 values of 0.63 µM and 0.77 µM for inducing IL-6 and IL-12 in mBMDCs, respectively. 1Z105 promotes dendritic cell maturation, antigen uptake and cross-presentation; when used alone, it induces Th2-IgG1, while combined with the TLR7 agonist 1V270, it synergistically induces balanced Th1/Th2 responses and provides low-reactogenic protection against homologous, heterologous and heterosubtypic influenza. 1Z105 prevents LPS (HY-D1056A1)- and galactosamine-induced liver injury as well as autoantibody-driven arthritis in mice. 1Z105 can be used in studies related to influenza virus infection, inflammation, and LPS/galactosamine-induced liver injury .
loading...
    loading...
View All Sizes
Assay Types